S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Forecast, Price & News

$1.70
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.70
▼
$1.78
50-Day Range
$1.72
▼
$2.16
52-Week Range
$1.70
▼
$13.60
Volume
8,545 shs
Average Volume
8,229 shs
Market Capitalization
$3.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BVXV stock logo

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

June 3, 2023 | americanbankingnews.com
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Expected to Earn FY2023 Earnings of ($0.01) Per Share
May 31, 2023 | americanbankingnews.com
Brokers Issue Forecasts for BiondVax Pharmaceuticals Ltd.'s Q2 2023 Earnings (NASDAQ:BVXV)
June 3, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 30, 2023 | finance.yahoo.com
BVXV: Developing anti-IL-17 NanoAb
May 28, 2023 | americanbankingnews.com
BiondVax Pharmaceuticals (NASDAQ:BVXV) Receives New Coverage from Analysts at StockNews.com
May 21, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)
May 15, 2023 | finanznachrichten.de
BiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 | msn.com
Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73
June 3, 2023 | Stansberry Research (Ad)
The gold catalyst we've waited for
Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
May 15, 2023 | finance.yahoo.com
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
April 26, 2023 | americanbankingnews.com
BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.com
April 20, 2023 | theglobeandmail.com
BiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team
April 19, 2023 | americanbankingnews.com
BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated at StockNews.com
April 18, 2023 | finanznachrichten.de
BiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
April 4, 2023 | marketwatch.com
BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
March 26, 2023 | marketwatch.com
BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
March 25, 2023 | americanbankingnews.com
BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.com
March 16, 2023 | finance.yahoo.com
BiondVax to Present at BIO-Europe Spring
March 6, 2023 | finance.yahoo.com
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
March 3, 2023 | finance.yahoo.com
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
February 2, 2023 | finance.yahoo.com
BiondVax Presenting at BIO CEO & Investor Conference
January 25, 2023 | benzinga.com
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
January 25, 2023 | benzinga.com
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
January 23, 2023 | markets.businessinsider.com
BiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In Hamsters
January 23, 2023 | finance.yahoo.com
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
January 23, 2023 | it.tmcnet.com
BiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
January 23, 2023 | finance.yahoo.com
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
See More Headlines

BVXV Price History

BVXV Company Calendar

Last Earnings
4/17/2023
Today
6/03/2023
Next Earnings (Estimated)
8/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BVXV
CUSIP
N/A
CIK
1611747
Web
www.biondvax.com
Phone
9723029302529
Fax
972-8930-2531
Employees
15
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,800,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-346.36%
Return on Assets
-28.48%

Debt

Debt-to-Equity Ratio
5.92
Current Ratio
4.28
Quick Ratio
4.28

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.58) per share
Price / Book
-0.67

Miscellaneous

Outstanding Shares
1,870,000
Free Float
1,755,000
Market Cap
$3.22 million
Optionable
Not Optionable
Beta
2.47

Key Executives

  • Amir Reichman
    Chief Executive Officer & Director
  • Elad Mark
    Chief Operating Officer
  • Uri Ben-Or
    Chief Financial Officer
  • Tamar Ben-Yedidia
    Chief Science Officer
  • Dalit Weinstein Fischer
    Head-Technical, Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













BVXV Stock - Frequently Asked Questions

How have BVXV shares performed in 2023?

BiondVax Pharmaceuticals' stock was trading at $2.96 at the start of the year. Since then, BVXV stock has decreased by 41.9% and is now trading at $1.72.
View the best growth stocks for 2023 here.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 18,000 shares, an increase of 20.8% from the April 30th total of 14,900 shares. Based on an average trading volume of 27,000 shares, the short-interest ratio is presently 0.7 days.
View BiondVax Pharmaceuticals' Short Interest.

When is BiondVax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023.
View our BVXV earnings forecast.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) released its quarterly earnings results on Monday, April, 17th. The company reported ($0.30) earnings per share for the quarter.

When did BiondVax Pharmaceuticals' stock split?

BiondVax Pharmaceuticals's stock reverse split before market open on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

Who are BiondVax Pharmaceuticals' major shareholders?

BiondVax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sabby Management LLC (17.45%).

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $1.72.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $3.22 million. The company earns $-5,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -